HomeCLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Category: CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Sedana Medical Completes Patient Recruitment...

"The completion of INSPiRE-ICU 2 concludes Sedana Medical´s clinical trials in the United States. Running this study together with esteemed clinical investigators from highly ranked academic centers such as Columbia, the Harvard-affiliated medical center Beth Israel Deaconess Medical Center and many others has been very exciting and rewarding. Many investigators from the participating sites have been excited to be part of our pioneering studies. The bedside experience in the studies has generated a lot of interest in using inhaled sedation in US practice, which we hope will be possible soon," said Peter Sackey, Chief Medical Officer of Sedana Medical.

Viz.ai and UTMB Announce Collaboration...

“Patient enrollment is the most time-consuming and costly aspect of the clinical trial process,” said Prem Batchu-Green, Vice President of Clinical at Viz.ai. “By deploying Viz.ai for the CHESS study, we are not only reducing the manual burden of patient identification on research staff but also improving SDH detection and workflow as well as increasing SDH awareness, physician engagement, clinical specialist attendance, and case collaboration.”

Sedana Medical Completes Patient Recruitment for its Clinical Program in the US

"The completion of INSPiRE-ICU 2 concludes Sedana Medical´s clinical trials in the United States. Running this study together with esteemed clinical investigators from highly ranked academic centers such as Columbia, the Harvard-affiliated medical center Beth Israel Deaconess Medical Center and many others has been very exciting and rewarding. Many investigators from the participating sites have been excited to be part of our pioneering studies. The bedside experience in the studies has generated a lot of interest in using inhaled sedation in US practice, which we hope will be possible soon," said Peter Sackey, Chief Medical Officer of Sedana Medical.

Unlocking New Hope: Alzheimer’s Patients Join Amyloid-Targeting Therapy Study

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

The research, presented at the American Society of Interventional Pain Physicians (ASIPP) Annual Meeting, included a registrational Phase 3 trial and an integrated safety analysis of six clinical studies, as well as a real-world analysis of current treatment options and gaps in the clinical management of patients with newly-diagnosed LDH.

Lunit’s AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening | Study in European Radiology Reveals

This comprehensive study encompassed over 22,621 mammograms from 8,825 women over a decade. Utilizing Lunit INSIGHT MMG, Lunit's AI-powered solution for breast cancer detection, the research aimed to assess its proficiency in early cancer detection within a breast cancer screening program.

Around 10% of Deaths from Coronary Stenting, Balloon Angioplasty Are Preventable | Complications During Procedures Only Contributed to Death in About 20% of Cases

Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally invasive procedure to unclog the arteries that feed the heart. While PCI, which includes both angioplasty and stenting, is one of the most common operations in the world, it does carry a small (about 1-2%) but significant risk of death. Around 10% of all deaths following percutaneous coronary intervention are potentially preventable, a study led by Michigan Medicine finds.

Data from Brainomix’s Collaboration with AstraZeneca Shows its AI-Powered e-Lung Better Identifies Lung Fibrosis Patients at Risk of Decline

The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.

Black Men May Be Less Likely to Receive a Heart Transplant than White Men, Women | According to JAMA Published Study

“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.

Mount Sinai Study Calls for Major Changes in the Way People With Comorbidities Are Selected by Physicians for Lung Cancer Screening

The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities

By using this website you agree to accept Medical Device News Magazine Privacy Policy